Although CLDN3 expression could be found in a wide range of tumor entities, it showed that CLDN3 positivity was most seen in neuroendocrine neoplasms and adenocarcinomas, as well as in tumors of the female genital tract and various subtypes of breast cancer. This evidence concerns the gene CLDN3 and breast cancer.